肝细胞癌肿瘤体积倍增时间:系统评价与荟萃分析
该系统评价与荟萃分析纳入20项研究、1334例患者的1374个肝细胞癌病灶,计算未干预治疗的肿瘤体积倍增时间(TVDT)。汇总TVDT为4.6个月(95%CI 3.9-5.3),35%为快速生长、27.4%为中间型、37.6%为惰性生长;亚洲人群TVDT较短。
要点
- 肝细胞癌汇总TVDT约4.6个月,但生长模式异质,快速生长占35%。
- 亚洲人群TVDT较其他地区短(4.1 vs 5.8个月)。
- 快速生长相关因素包括乙肝病因、较小肿瘤、AFP倍增时间及低分化。
核心结论
- 肝细胞癌TVDT约为4-5个月,但生长模式存在异质性,亚洲乙肝流行人群更具侵袭性。
研究设计与样本
- 纳入20项报告未干预治疗肝细胞癌肿瘤生长或TVDT的研究,共1374个病灶、1334例患者。
- 采用随机效应模型计算汇总TVDT,快速生长定义为TVDT<3个月,惰性生长定义为TVDT>9个月。
主要发现
- 汇总TVDT为4.6个月(95%CI 3.9-5.3个月,I2=94%)。
- 35%病灶为快速生长,27.4%为中间型,37.6%为惰性生长。
- 亚洲研究报道的TVDT短于其他地区(4.1 vs 5.8个月)。
- 快速肿瘤生长最一致的相关因素包括乙肝病因、较小肿瘤尺寸(连续变量)、甲胎蛋白倍增时间和肿瘤低分化。
临床怎么用
- TVDT数据可用于个体化制定肝细胞癌监测间隔和预后判断,尤其需关注乙肝相关快速生长模式。
局限性
- 研究受样本量小、测量偏倚和选择偏倚限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour growth patterns have important implications for surveillance intervals, prognostication and treatment decisions but have not been well described for hepatocellular carcinoma (HCC). The aim of our study was to characterise HCC doubling time and identify correlates for indolent and rapid growth patterns. METHODS: We performed a systematic literature review of Medline and EMBASE databases from inception to December 2019 and national meeting abstracts from 2010 to 2018. We identified studies reporting HCC tumour growth or tumour volume doubling time (TVDT), without intervening treatment, and abstracted data to calculate TVDT and correlates of growth patterns (rapid defined as TVDT <3 months and indolent as TVDT >9 months). Pooled TVDT was calculated using a random-effects model. RESULTS: We identified 20 studies, including 1374 HCC lesions in 1334 patients. The pooled TVDT was 4.6 months (95% CI 3.9 to 5.3 months I2=94%), with 35% classified as rapid, 27.4% intermediate and 37.6% indolent growth. In subgroup analysis, studies from Asia reported shorter TVDT than studies elsewhere (4.1 vs 5.8 months). The most consistent correlates of rapid tumour growth included hepatitis B aetiology, smaller tumour size (continuous), alpha fetoprotein doubling time and poor tumour differentiation. Studies were limited by small sample sizes, measurement bias and selection bias. CONCLUSION: TVDT of HCC is approximately 4-5 months; however, there is heterogeneity in tumour growth patterns, including more aggressive patterns in Asian hepatitis B-predominant populations. Identifying correlates of tumour growth patterns is important to better individualise HCC prognostication and treatment decisions.
引用
- Nathani P, Gopal P, Rich N, et al. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut. 2020. PMID: 32398224. doi:10.1136/gutjnl-2020-321040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。